Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial
Byoung Chul Cho(Yonsei University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Sergey Efuni(Oncoceutics (United States)), Svetlana Shpyro(BioNTech (Germany)), Jennifer L. Leddon(University of Cincinnati), Uğur Şahin(Johannes Gutenberg University Mainz), Tianhong Li(VA Northern California Health Care System), Mark A. Socinski(Florida Hospital Cancer Institute), Adewale Fawole(Florida Cancer Specialists & Research Institute), Xi-Cheng Wang(First Affiliated Hospital of Guangdong Pharmaceutical University), Meili Sun(Jinan Central Hospital), Yang Liu(Mudanjiang Medical University), George Zhang(Air Force Medical University), Rama Balaraman(Cardiovascular Institute of Central Florida), Keon-Uk Park(Keimyung University Dongsan Hospital), Zhi-gang Liu(Third Affiliated Hospital of Southern Medical University), Long Wu(Wuhan University), Preet Singh(Springfield Clinic), Kai He(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Youngjoo Lee(Chungbuk National University Hospital), Hua-Jun Chen(Guangdong Academy of Medical Sciences), Xinmin Yu(Zhejiang Cancer Hospital), Shiling Song(Oncoceutics (United States)), John Hamm(Norton Healthcare), Michael Wenger(BioNTech (Germany)), Andrew Beardsley(Cancer Care of Western North Carolina), Youngjoo Lee(National Cancer Center), Pan Zheng(Oncoceutics (United States)), Kun He(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Pinhua Pan(Central South University), Bin Yang(Hubei Cancer Hospital), Vikram Jain(Mater Adult Hospital), Kai He(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Qiong Wang(BioNTech (United States)), Lin Wu(Wuhan University), Yan Yu(Harbin Medical University), Luchun Li(Chongqing Cancer Hospital), Long Wu(Wuhan University), Ardalan Davarifar(University of Tennessee Medical Center), Yanjing Huang(Hainan General Hospital), Fadi Kayali(Florida Cancer Specialists & Research Institute)
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k